Skip to Content
Current OncologyCurrent Oncology
  • Article
  • Open Access

12 August 2026

13 Pages

Impact of Chronic Kidney Disease Stages 3–5 on Mortality and Morbidity Outcomes in Patients with Esophageal Cancer: A Propensity-Score-Matched Cohort Study

,
and
1
Division of Thoracic Surgery, Department of Surgery, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 111045, Taiwan
2
Division of Nephrology, Department of Internal Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 111045, Taiwan
3
Department of General Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 111045, Taiwan
4
Division of Digital Informatics Management, Department of Digital Medicine, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei 111045, Taiwan
This article belongs to the Section Gastrointestinal Oncology

Simple Summary

Patients with esophageal cancer often need intensive treatment and supportive care. Kidney disease may make treatment more difficult because it is linked to anemia, cardiovascular disease, and reduced physiologic reserve. In this large electronic health record study, we compared adults with esophageal cancer who had clinically recorded chronic kidney disease stages 3–5 with similar adults without chronic kidney disease. Kidney disease was not associated with uniformly worse outcomes; instead, it was linked mainly to higher rates of blood transfusion and cardiovascular events, while more advanced kidney disease was linked to higher mortality. These findings suggest that kidney function should be considered when planning supportive care and risk counseling for patients with esophageal cancer.

Abstract

Chronic kidney disease (CKD) may reduce physiologic reserve among patients with esophageal cancer, but evidence beyond postoperative cohorts is limited. Using the TriNetX Global Collaborative Network, we studied adults with esophageal cancer diagnosed during 2010–2023. CKD stages 3–5 were defined by diagnostic codes plus estimated glomerular filtration rate < 60 mL/min/1.73 m2 within 6 months before or on the index date; dialysis-dependent patients were excluded. Non-CKD patients served as comparators. Prespecified outcomes from day 1 to up to 3 years included all-cause mortality, subsequent recorded metastatic diagnosis, pneumonia, sepsis, blood transfusion, and major adverse cardiovascular events. Propensity score matching produced 832 pairs. All-cause mortality was not significantly higher in the overall cohort with CKD stages 3–5 than in the non-CKD cohort (HR, 1.13; 95% CI, 0.98–1.31; p = 0.099), whereas CKD stages 4–5 were associated with higher mortality in the stage-specific analysis (HR, 1.46; 95% CI, 1.03–2.06; p = 0.031). CKD stages 3–5 were also associated with higher risks of blood transfusion (HR, 1.45; 95% CI, 1.04–2.01; p = 0.025) and MACEs (HR, 1.22; 95% CI, 1.02–1.47; p = 0.027), and with a lower risk of subsequent recorded metastatic diagnosis (HR, 0.80; 95% CI, 0.65–0.99; p = 0.036). These findings suggest that the associations of CKD with post-diagnostic outcomes varied by outcome type, with higher mortality observed in the separate CKD stages 4–5 analysis.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.